Lexicon Pharmaceuticals, Inc. (LXRX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in The Woodlands, TX, United States. The current CEO is Michael S. Exton.
LXRX has IPO date of 2000-04-07, 103 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $741.44M.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
